JP Morgan Upgrades Teva Pharmaceutical Indus to Neutral, Announces $14 Price Target
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Chris Schott upgraded Teva Pharmaceutical Industries (NYSE:TEVA) from Underweight to Neutral and set a $14 price target.
March 08, 2024 | 1:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Teva Pharmaceutical Industries upgraded by JP Morgan to Neutral with a $14 price target.
Upgrades by major financial institutions like JP Morgan can lead to increased investor confidence and potentially drive up the stock price in the short term. The upgrade from Underweight to Neutral suggests a more favorable outlook on TEVA by JP Morgan, which could influence market sentiment positively. The setting of a $14 price target further indicates an expectation of upward movement in TEVA's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100